**Latin American Journal of Clinical Sciences and Medical Technology is an open access magazine.

To read all published articles and materials you just need to register

Registration is free of charge.   Register now

If you already have registered please   Log In
**
Thursday September 11th, 2025
Latin American Journal of Clinical Sciences and Medical Technology
Index
Partnerships
DADI Salud
Published Volumes
Submit & Guides for Authors
Authors / Reviewers Access
Editorial Board
Register
Log In
Case Report

Josué Saúl Almaraz Lira (0000-0002-1502-0157)a; Alfredo Luis Chávez Haro (0000-0002-6391-8375)a; Cristian Alfredo López López (0000-0002-1362-6577)a; Remedios del Pilar González Jiménez (0000-0002-2152-0131)a.
aCruz Roja Mexicana, León Delegation; Scorpion Center, León, Guanajuato; México.
Corresponding Author: , . Telephone number: ; e-mail: js.almarazlira@ugto.mx

Citation: Almaraz Lira JS, Chávez Haro AL, López López CA, González Jiménez RP. Descending Cervical-Sacral Pain after the Administration of Antivenom to the Scorpion Sting Poisoning: A Case Report.
Lat Am J Clin Sci Med Technol. 2020 Jun;2:93-96.
Received: April 20th, 2020.
Accepted: May 22nd, 2020.
Published: June 3rd, 2020.
Views: 744
Downloads: 17
ABSTRACT

Introduction. Scorpion stings occur mainly in spring and summer, with an estimate of approximately 1.2 million cases per year worldwide. About 300,000 poisonings occur within a year, primarily affecting children and adults older than 65 years. In 2019, Guanajuato (Mexico) ranked third in poisoning by scorpion sting with a total of 43,913 cases. The intoxication grades are three where the signs and symptoms are varied. There are two types of antivenom in the Mexican market, and we use Alacramyn® in our case. Case presentation. A 70-year-old female —with grade 1 scorpion sting poisoning, 30 minutes of evolution, with type 2 diabetes and high blood pressure— received two vials of antivenom according to current regulations. She presented transient vagal reaction and subsequent transient pain in the cervical region that radiates to the sacral region. At discharge, there are no data compatible with scorpion sting poisoning. Conclusions. Transient pain in the cervical region to the sacral region may be secondary to an anxiety crisis, hypersensitivity to IgG, or secondary reaction to administration in less time than recommended by the provider. The benefit was greater than the reactions that occurred.

Keywords: scorpion sting, antivenom, cervical pain, medication errors

RESUMEN

Introducción. Las picaduras de alacrán ocurren principalmente en primavera y verano, con una estimación de aproximadamente 1.2 millones de casos anuales a nivel mundial. En un año, ocurren aproximadamente 300,000 intoxicaciones que afectan principalmente a niños y adultos mayores de 65 años. En 2019, Guanajuato (México) fue el tercer lugar en intoxicaciones por picadura de alacrán con un total de 43,913 casos. Los grados de intoxicación son tres en donde los signos y síntomas son variados. Existen dos tipos de antiveneno en el mercado mexicano, nosotros usamos Alacramyn® en nuestro caso. Presentación del caso. Femenina de 70 años de edad, con intoxicación por picadura de alacrán grado 1, de 30 minutos de evolución, con diabetes tipo 2 e hipertensión arterial; se le administran dos viales de antiveneno de acuerdo con la normativa vigente. Presenta reacción vagal transitoria y posterior dolor transitorio en región cervical que se irradia hasta región sacra. Al egreso no presenta datos de compatibles con intoxicación por picadura de alacrán. Conclusiones. El dolor transitorio en región cervical hasta región sacra puede ser secundario a una crisis de ansiedad, hipersensibilidad a la IgG o reacción secundaria a la administración en menor tiempo del recomendado por el proveedor. El beneficio fue mayor a las reacciones que se presentaron.

Palabras clave: picadura de alacrán, antiveneno, dolor cervical, error de medicación

INTRODUCTION

Scorpion sting accidents occur mainly in tropical or subtropical climatic regions, or the spring or summer season1,2. The clinical picture is extensive due to sting poisoning.3 There is an estimation of 1.2 million poisonings per year.4

The poisoning by scorpion sting ranks within the 20 major public health problems in Mexico, primarily affecting children and adults older than 65 years, that is to say, about 300,000 poisonings during a year in the national territory. The incidence rate at the national level was 245.46 per 100,000 habitants in 2010, while in 2015 was 222.33 cases of poisoning by a scorpion sting.2 The only specific treatment for this pathology is antivenom.5-8

Guanajuato is one of the states in Mexico with the highest number of reported cases of poisoning due to scorpion sting, with 43,913 poisonings in 2019, just below Jalisco with 46,554 and Guerrero 45,621 cases.9

In Mexico, the mortality estimated was 6,077 deaths between 1979 and 200310; 209 deaths from 2006 to 2012 with an incidence rate of 12.4 per 100,000 inhabitants.11

According to the Official Regulations, the clinical practice guidelines (Manual de procedimientos estandarizados para la vigilancia epidemiológica de la intoxicación por picadura de alacrán, Handbook of Standardized Procedures for Epidemiological Surveillance of Scorpion Sting Poisoning) group the signs and symptoms as follows3,5,11:

  • Slight. Local pain, local paresthesias, itching, mild restlessness.
  • Moderate. Most of the slight symptoms and persistent crying in children younger than five years old; anguish, headache, epiphora, redness of the eye, itching of the nose, mouth, and throat, sneezing, runny nose, sialorrhea, foreign body sensation in the throat, dysphagia, lingual fasciculations, dry mouth, tachycardia, dyspnea, bloating, abdominal and muscle pain, priapism, vulvar itching.
  • Severe. Moderate symptoms and hypertension or arterial hypotension, fever or hypothermia, miosis, mydriasis, photophobia, nystagmus, dyslalia, perioral cyanosis, seizures, temporary amaurosis, bradycardia, arrhythmias, retrosternal pain, oliguria, unconsciousness, multiple organ failure, coma, death.

People younger than five years old, older than 60 years, malnourished, diabetics, hypertensive patients, with nephropathy, and pregnant women are included in the high-risk groups.5

In Mexico, there are two scorpion sting poison antivenoms in the market: Birmex®, manufactured by Laboratorios de Reactivos y Biológicos de México, S.A. de C.V.; and Alacramyn®, produced by Instituto Bioclon, both with a neutralizing efficacy of 150 LD50 per vial.12,13

Case Report

A 70-year-old female enters the Emergency Service at Cruz Roja Mexicana, León Delegation, due to scorpion sting intoxication. She states that it was the first time she had been stung by a scorpion; it took 30 minutes from the accident site until arrival at the hospital. She did not take any home remedies. She has type II diabetes and systemic arterial hypertension; she takes telmisartan and metformin. She denies allergies. Vital signs were 140/90 mmHg blood pressure, 20 breaths per minute, 74 beats per minute, 93% saturation of O2. A score of 15 on the Glasgow Coma Scale. Signs and symptoms were: low temperature at the site of the sting (32.2°C versus the contralateral site 33.0°C), pain at the site of the sting (distal phalanx of the fourth finger of the right hand), with a score 4/10 on the Visual Analog Scale (VAS) of pain, paresthesia in the stung site. On examination, a normocephalic skull without endostosis or exostosis, isochoric and reflective pupils, hydrated mucosa, no jugular engorgement, no attached murmurs, eutrophic extremities, were observed.

Treatment

According to the current regulations, two vials of F(ab)2 fragments of polyvalent anti-scorpion immunoglobulin (Alacramyn®) were indicated for present comorbidities. Consistent with our experience, they were stored at room temperature and were intravenously administered at an interval of 30 seconds in a ten cc syringe with a physiological solution at 0.9%.14 Analgesic was not administered because of the low effectiveness that we have at the institution.15 The vagal reaction occurred 30 seconds after administration and ceased after 60 seconds. Thirty seconds later, the pain began in the cervical region descending to the sacral region, which persisted for about 60 seconds, remitting on its own.

Discharge Diagnosis

After 120 minutes without requiring a new antidote dose, she was discharged because she did not present any symptom of intoxication, except for pain with a VAS 2/10, heart rate of 72, respiratory rate of 16 and blood pressure of 130 / 80 mmHg, with a diagnosis of remitted scorpion sting poisoning.

CONCLUSIONS

The most common symptoms are pain at the site of the bite in 98%16, hives, rash, bronchospasm, or anaphylactoid reaction, described as IgG-mediated type 1 hypersensitivity side reactions.17,18 Pain in the cervical region descending to the sacral region had not been previously described as a reaction by medication error after the administration of F(ab´)2 fragments of polyvalent anti-scorpion immunoglobulin. Thus, after the vagal event, it is likely the reaction was the product of an anxiety crisis, unrelated to the antidote administration. Other pathologies —like cervical spondylosis, distortion of sacroiliac joints o arthrosis at the level of the cervical pain— may be consistent with the type of pain the patient presented. The pain was triggered by the activation of an unidentified pain receptor, after the use of antivenom.

Patients with comorbidities are administered twice as many antidotes the case being reported herein.5

The antivenom, at the specified temperature for a more extended period, is not altered in terms of its sterility or efficacy according to the Official Regulations.3,19 The infusion rate, according to the information for a prescription, is to fill in 50 ml of physiological solution and administer it in 30 minutes20, contradicting the indication of “(…) observation for 20 minutes; if there is no improvement, apply another bottle”. Third-generation antidotes such as those used are purified by enzymatic digestion with pepsin21, reach a high purity, and cause few side reactions (0.2%) previously reported.17

Serum sickness associated with type 3 immunological reactions, characterized by hives and arthralgias, has been described, presenting only in 0.8% of the users who received the antidote17,18, which is not compatible with the symptoms of the present study.

In this case, antivenom was used due to the symptoms presented by the user and the previous pathologies, having a greater benefit than the reactions shown. For future studies, it is recommended to register patients with similar symptoms to determine the frequency of the responses to the use of F(ab´)2 fragments of polyvalent anti-scorpion immunoglobulin because they are rare. It is also essential to register the time of administration according to the official regulations.

Medication error was classified as mild because it was not necessary to administrate another drug for the symptoms presented after administering the vial22, the length of the hospital day was similar to other users.23

Knowing these signs and symptoms will increase the speed to improve the care protocols for patients with scorpion sting poisoning, particularly in Mexico, a country with high morbidity and mortality from a scorpion sting, where this reaction had not been reported.

ACKNOWLEDGMENTS

We are grateful to Laura Alejandra Lugo-Sánchez for assistance.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

REFERENCES

1.Hurtado-Díaz M, Guzmán-Ontiveros J, Arias-Medellín LA, Hernández-Cadena L, Moreno-Banda GL, Rodriguez-Dozal SL, et al. Influence of increasing temperature on the scorpion sting incidence by climatic regions. Int J Climatol [Internet]. 2018 Apr 1 [cited 2020 May 20];38(5):2167–73. Available from: http://doi.wiley.com/10.1002/joc.5318
2.Almaraz-Lira JS, Chávez-Haro AL. Relación de la temperatura máxima, temperatura mínima y pluviometría por regiones climáticas sobre la incidencia de picadura de alacrán en México, 2010-2018. Rev Hosp Med Clin Manag. 2019 Nov 25;12(4):157–64.
3.DOF - Diario Oficial de la Federación. NORMA Oficial Mexicana NOM-033-SSA2-2011, Para la vigilancia, prevención y control de la intoxicación por picadura de alacrán. 2011. p. 1–13.
4.Chippaux JP, Goyffon M. Epidemiology of scorpionism: A global appraisal. Acta Trop. 2008 Aug;107(2):71–9.
5.Secretaría de Salud. Guía de práctica clínica. Prevención, diagnóstico, tratamiento y referencia de la intoxicación por picadura de alacrán [Internet]. 2015. Available from: http://www.cenetec-difusion.com/CMGPC/SS-148-08/ER.pdf
6.Chávez-Haro AL, Ortiz E. Scorpionism and dangerous species of mexico. In: Scorpion Venoms. Springer Netherlands; 2015. p. 201–13.
7.Tay Zavala J, Díaz Sánchez JG, Vega S, Castillo A, Ruíz D CL. Picaduras por alacranes y arañas ponzoñosas de México. Rev Fac Med UNAM. 2004;47(1):6–12.
8.Riaño-Umbarila L, Rodríguez-Rodríguez ER, Santibañez-López CE, Güereca L, Uribe-Romero SJ, Gómez-Ramírez I V., et al. Updating knowledge on new medically important scorpion species in Mexico. Toxicon. 2017 Nov 1;138:130–7.
9.Gobierno de México. Boletín Epidemiológico Sistema Nacional de Vigilancia Epidemiológica Sistema Único de Información. Semana 52| Secretaría de Salud | Gobierno | gob.mx [Internet]. [cited 2020 May 20]. Available from: https://www.gob.mx/salud/documentos/_-boletinepidemiologico-sistema-nacional-de-vigilancia-epidemiologica-sistema-unico-de-informacion
10.Celis A, Gaxiola-Robles R, Sevilla-Godínez E, Valerio M de JO, Armas J. Trends in mortality from scorpion stings in Mexico, 1979-2003. Rev panam salud pública. 2007;21(6):373–80.
11.Secretaría de Salud. Dirección General de Epidemiología Manual de Procedimientos Estandarizados para la Vigilancia Epidemiológica de la Intoxicación por Picadura de Alacrán. 2012; 1-60.
12.Laboratorios de Biológicos y Reactivos de México.Ficha Técnica. Faboterápico polivalente antialacrán [Internet]. Available from: https://www.birmex.gob.mx/assets/faboterápico-antialacrán.pdf
13.Instituto Bioclon. Producto Alacramyn. Faboterápico Polivalente Antialacrán [Internet]. Available from: www.biodiagnosticos.com
14.D´Suze, Gina, Corzo-Burguete GA P-SJ. Alacranismo en León, Guanajuato, México. In: Emergencias por animales ponzoñosos en las Américas. México: Innova, CONACYT; 2011.
15.Almaraz-Lira JS, Chávez-Haro AL, García-Guardado DI, Campos-Montoya S, Salgado-López RI R-TM. Ensayo clínico aleatorizado controlado de ketorolaco, metamizol sódico y clonixinato de lisina en dolor asociado a picadura de alacrán. Rev Med MD [Internet]. 2020 [cited 2020 May 20];11(3):211–6. Available from: https://revistamedicamd.com/cnt/Trabajos Originales/Ensayo-cl-nico-aleatorizado-controlado-de-ketorolaco-metamizol-s-dico-y-clonixinato-de-lisina-en-dolor-asociado-a-picadura-de-alacr-n-
16.Osnaya-Romero N, de Jesus Medina-Hernández T, Flores-Hernández SS, León-Rojas G. Clinical symptoms observed in children envenomated by scorpion stings, at the children’s hospital from the State of Morelos, Mexico. Toxicon. 2001;39(6):781–5.
17.Boyer L, Degan J, Ruha AM, Mallie J, Mangin E, Alagón A. Safety of intravenous equine F(ab’)2: Insights following clinical trials involving 1534 recipients of scorpion antivenom. Toxicon. 2013 Dec 15;76:386–93.
18.Norma Oficial Mexicana NOM-036-SSA2-2012, Prevencion y control de enfermedades. Aplicación de vacunas, toxoides, faboterápicos (sueros) e inmunoglobulinas en el humano. [Internet]. 28 de septiembre. 2012. p. 1–55. Available from: https://www.cndh.org.mx/DocTR/2016/JUR/A70/01/JUR-20170331-NOR35.pdf
19.Elhag DE, Mahmoud RAK. Efficacy and Stability of Scorpion Antivenom: At Different Storage Conditions. Pharm Anal Acta 2017;8(12): 570.
20.PLM. Alacramyn [Internet]. [cited 2020 May 20]. Available from: https://www.medicamentosplm.com/Home/productos/alacramyn_solucion_inyectable/79/101/6181/162
21.Laustsen AH, María Gutiérrez J, Knudsen C, Johansen KH, Bermúdez-Méndez E, Cerni FA, et al. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. Toxicon. 2018 May 1;146:151–75.
22.NORMA Oficial Mexicana NOM-220-SSA1-2016, instalación y operación de la farmacovigilancia [Internet]. 2016 [cited 2018 Aug 29]. Available from: http://www.dof.gob.mx/nota_detalle.php?codigo=5490830&fecha=19/07/2017
23.Chávez-Haro AL, Almaraz-Lira JS, González-Canudas JA, Molina-Perez A, Amador-Hernández AG, Garcia-Ubbelohde W. Change of Temperature at Sting Site by Scorpion in León, Guanajuato. Ann Clin Toxicol [Internet]. 2019 Apr 1 [cited 2020 May 20];2(1):11–5. Available from: http://www.remedypublications.com/open-access/change-of-temperature-at-sting-site-by-scorpion-in-len-guanajuato-1121.pdf


All Rights Reserved® 2019

Latin American Journal of Clinical Sciences and Medical Technology,
Publicación contínua    Editor responsable: Gilberto Castañeda Hernández.    Reserva de Derechos al Uso Exclusivo: 04-2019-062013242000-203; ISSN: 2683-2291; ambos otorgados por el Instituto Nacional del Derecho de Autor.    Responsable de la última actualización de este número, Web Master Hunahpú Velázquez Martínez,
Calle Profesor Miguel Serrano #8, Col. Del Valle, Alcaldía Benito Juárez, CP 03100, Ciudad de México, México. Número telefónico: 55 5405 1396    Fecha de última modificación, 28 de agosto de 2024.
Contact us   |   Privacy policy   |   Legal Information

All Rights Reserved® 2019

Latin American Journal of Clinical Sciences and Medical Technology,
Publicación contínua    Editor responsable: Gilberto Castañeda Hernández.    Reserva de Derechos al Uso Exclusivo: 04-2019-062013242000-203; ISSN: 2683-2291; ambos otorgados por el Instituto Nacional del Derecho de Autor.    Responsable de la última actualización de este número, Web Master Hunahpú Velázquez Martínez,
Calle Profesor Miguel Serrano #8, Col. Del Valle, Alcaldía Benito Juárez, CP 03100, Ciudad de México, México. Número telefónico: 55 5405 1396    Fecha de última modificación, 28 de agosto de 2024.